Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.
FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2026 Rachel Fremont, Marcella Corwin, Greta Kandel et al.
Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...
DOI: 10.1176/appi.focus.20250046 (opens in new tab)
Full text (opens in new tab)
Depression
Esketamine
Academic psychiatry
Antidepressants